Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x receptor, protein that regulates metabolism, can reduce inflammation and protect dopamine neurons.
This study hypothesizes that drugs targeting the farnesoid x receptor that are currently in clinical trials for other purposes will reduce neuroinflammation in pre-clinical models of Parkinson's.
We will use two pre-clinical models of PD that both have significant inflammatory components. Existing drugs/compounds that target the farnesoid x receptor will be administered to determine whether they can reduce inflammation and protect dopamine neurons from dying.
Next Steps for Development:
If our experiments are successful, these drugs may progress to clinical trials for Parkinson's more rapidly, as they have been in clinical trials for other conditions.